hydroxychloquine sulphate in oral liquid bases

Published: 9 November 2020| Version 2 | DOI: 10.17632/yznh3nzg8b.2
Contributors:
Nunzio Denora,
Valentino Laquintana,
Angela Lopedota,
Annalisa Cutrignelli,
Antonio Lopalco,
Massimo Franco,
Antonio Pepe,
Sergio Fontana

Description

Stability data of extemporaneous suspensions of hydroxychloquine sulphate in oral liquid bases after tablet manipulation. Hydroxychloroquine is a well-known antimalarial and anti-rheumatic drug that has garnered unprecedented attention as potential therapeutic agent against COVID-19. Hydroxychloroquine sulphate is used off-label as lifetreating medicine for COVID-19 patients and is authorized in the EU as film-coated tablets (i.e. Plaquenil®), which cannot be administered to non-cooperative patients, such as those in intensive care units or, more in general, unable to swallow solid dosage forms. Therefore, the hospital pharmacist must manipulate the solid dosage form for the preparation of suspension, even if it can strongly affect the product quality. In this scenario, it is crucial to offer useful information and advice to assist hospital pharmacists in their activity. The data presented in this article suggest that extemporaneous suspensions of hydroxychloquine sulphate in oral liquid bases (fast oral solution, named Puccini and fast oral solution - sugar free, named Beethoven) after tablet manipulation are stable for at least 30 days.

Files